A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (
about
Chemotherapy for brain metastases from small cell lung cancerUpdates of mTOR inhibitorsTargeting the mTOR signaling network for cancer therapySmall cell lung cancer (SCLC): no treatment advances in recent yearsGenomic profiling of small-cell lung cancer: the era of targeted therapiesJudicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and PerspectivesNew and emerging developments in extensive-stage small cell lung cancer therapeuticsPI3K/PTEN signaling in angiogenesis and tumorigenesisA pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621.Increased expression of Id1 and Id3 promotes tumorigenicity by enhancing angiogenesis and suppressing apoptosis in small cell lung cancerRapamycin selectively reduces the association of transcripts containing complex 5' UTRs with ribosomes in C4-2B prostate cancer cells.Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.Small cell lung cancer: therapies and targetsIncidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysisTargeted therapies in small cell lung cancer: a reviewChemotherapy for small cell lung cancer: a comprehensive reviewTargeted therapies for non-small cell lung cancer: an evolving landscape.Expression of phosphorylated mTOR and its clinical significances in small cell lung cancerNew molecular targeted therapies for advanced non-small-cell lung cancer.Small cell lung cancer: will recent progress lead to improved outcomes?Immunotherapy treatments for small-cell lung cancer: past, present and future.Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis.Metabolic complications with the use of mTOR inhibitors for cancer therapyNeurotoxicity of biologically targeted agents in pediatric cancer trialsSmall Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?Novel compounds in the treatment of lung cancer: current and developing therapeutic agents.Decursin and Doxorubicin Are in Synergy for the Induction of Apoptosis via STAT3 and/or mTOR Pathways in Human Multiple Myeloma Cells.The development of targeted therapy in small cell lung cancer.Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibitionCisplatin-Based Chemotherapy Options for Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck.Akt signals through the mammalian target of rapamycin pathway to regulate CNS myelination.A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma.Emerging drugs for small-cell lung cancer.Profiling of phospho-AKT, phospho-mTOR, phospho-MAPK and EGFR in non-small cell lung cancer.Targeting the Mammalian Target of Rapamycin in Lung Cancer.The biological and therapeutic relevance of mRNA translation in cancer.Update on new drugs in small cell lung cancer.
P2860
Q24202771-89875B24-B767-486D-81EF-16701542D43CQ24607170-80457F17-8739-440D-A76D-B5812220332CQ24658334-8EE1046C-2205-49B4-9540-3C6A8FD5EDE5Q26767020-09CDB158-EEF7-4D9C-A839-E200A0B093ABQ26826915-6CD38D0A-07A7-4308-8061-1EE79664A78FQ28071388-C099F773-ACA8-4EA6-9FCC-3CDC3874CAEBQ28076304-CD803598-206C-43F9-9474-752DBA767BEEQ28383083-DD800B75-C78A-4090-B5A5-69E31CCDC342Q33389796-71E2D2E4-C893-49A3-801B-2495B8BBEB58Q33416075-DAC90E91-63BB-454F-8FCA-D77C713AF54CQ33925346-CF2DFC12-397A-445F-A12B-C80C17FA7270Q34033097-E239FF56-9896-43A3-A599-3F134B5B5759Q34122718-70E144CD-9CE8-4910-8F38-9F4FB542C5BAQ34134584-F2BC6C57-03BE-492A-B891-0D17A9A9CBFDQ34250859-7D5498D6-0D02-4D28-B066-5EE55C7569B3Q34778631-E1972157-C3A1-4EC0-B584-CB6902CE6B4AQ35076234-CD4321A4-0D35-472F-B5A5-598F3136E4BCQ35569379-6FF9307D-09B5-4F7E-BF31-C2A309F2DCE5Q35628597-5A1A60D1-10EB-433D-9A89-D6D7A08BC76DQ35632245-1B2824BB-7B36-4803-9664-042D2D4014EDQ35667806-0C460EA0-11CB-4FF9-8493-2A339CED6C89Q35836257-2F919D61-0EB9-493F-9392-775D86D3915FQ35904003-EC22D181-A8D2-4B45-851F-E050DFEDD774Q36035933-EAF096F1-C7F4-47D4-8E77-408AC41DE4DBQ36553511-EE3462ED-098D-490F-8D81-BF8ED334327DQ36553517-4780C2B3-3ECC-477A-AD67-AACC416D9DDEQ36766221-609A274F-FA40-49F8-BF40-752C5C9D060CQ36811784-9D44CBA6-1E03-4B62-96FD-D7942AB44B3CQ36890658-EABFA6BD-8FD8-4CE5-82CD-4DCFF7102017Q36933281-20681970-C292-49B9-9A14-B1601D827276Q37127932-E61103DB-B9F1-4C9D-A8BF-C416A7EF6A4CQ37253319-0888195C-71E8-4F22-AA2C-00FFEBCE46FDQ37328494-18D147E2-0F59-48FA-B631-95ACB6877E59Q37377107-E7B82A59-B380-4384-B599-95E2671A9567Q37383599-DCB57D9E-25E2-4637-864F-84119FA36B32Q37582918-9FCCE965-DCCE-46D8-B34B-2F7795C2AC76Q37733727-3ABDA85C-B5C3-45C6-BC59-70ED1E9B0446Q37741531-242BF590-43C9-4191-BC32-22EAFA31AE57Q37848652-CC22CCCA-8C35-4192-A0CF-29B85BE71830Q37851992-38A7C5E0-518F-4030-B3BE-C7DA21A1D62E
P2860
A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
A randomized, phase II trial o ...... n Cooperative Oncology Group (
@ast
A randomized, phase II trial o ...... n Cooperative Oncology Group (
@en
type
label
A randomized, phase II trial o ...... n Cooperative Oncology Group (
@ast
A randomized, phase II trial o ...... n Cooperative Oncology Group (
@en
prefLabel
A randomized, phase II trial o ...... n Cooperative Oncology Group (
@ast
A randomized, phase II trial o ...... n Cooperative Oncology Group (
@en
P2093
P1476
A randomized, phase II trial o ...... erative Oncology Group (E1500)
@en
P2093
David H Johnson
Eastern Cooperative Oncology Group (E1500)
Joan H Schiller
Kishan J Pandya
Martin W Lee
Roger B Cohen
P304
P356
10.1097/JTO.0B013E318155A439
P577
2007-11-01T00:00:00Z